Assignee
PROTAGONIST THERAPEUTICS INC
US·30 granted patents·41 pending applications·493 citations·filing 2013–2025
Top patents by PatentIndex Score
71 records- 0198US11111272B2α4α7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Sep 7, 2021·10 cites·14 claims
- 0298US10626146B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Apr 21, 2020·15 cites·22 claims
- 0398US9518091B2A4B7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Dec 13, 2016·34 cites·21 claims
- 0497US10941183B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Mar 9, 2021·13 cites·20 claims
- 0597US10301371B2Cyclic monomer and dimer peptides having integrin antagonist activityPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted May 28, 2019·19 cites·14 claims
- 0697US10196424B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Feb 5, 2019·26 cites·22 claims
- 0797US10059744B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Aug 28, 2018·22 cites·31 claims
- 0897US10035824B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 31, 2018·24 cites·26 claims
- 0997US10023614B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 17, 2018·23 cites·21 claims
- 1097US9809623B2α4β7 peptide monomer and dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Nov 7, 2017·26 cites·14 claims
- 1197US9714270B2a4B7 integrin thioether peptide antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Jul 25, 2017·27 cites·22 claims
- 1297US9624268B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2015·Granted Apr 18, 2017·40 cites·24 claims
- 1396US11472842B2Analogues of hepcidin mimetics with improved in vivo half livesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Oct 18, 2022·5 cites·11 claims
- 1496US10030061B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Jul 24, 2018·29 cites·24 claims
- 1595US11807674B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Nov 7, 2023·3 cites·4 claims
- 1695US11041000B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Jun 22, 2021·13 cites·26 claims
- 1795US10729676B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Aug 4, 2020·10 cites·18 claims
- 1895US10501515B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Dec 10, 2019·18 cites·30 claims
- 1995US10442846B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted Oct 15, 2019·19 cites·19 claims
- 2095US9822157B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2014·Granted Nov 21, 2017·35 cites·9 claims
- 2195US9273093B2α4β7 peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2013·Granted Mar 1, 2016·31 cites·8 claims
- 2294US10278957B2Opioid agonist peptides and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2018·Granted May 7, 2019·16 cites·19 claims
- 2393US10787490B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·18 cites·18 claims
- 2491US10407468B2Methods for synthesizing α4β7 peptide antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2017·Granted Sep 10, 2019·13 cites·24 claims
- 2588US11840581B2α4β7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2020·Granted Dec 12, 2023·1 cites·17 claims
- 2688US2024199700A1Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2787US12269856B2Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·15 claims
- 2886US11753443B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·3 cites·10 claims
- 2986US2024209026A1A4b7 thioether peptide dimer antagonistsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3079US2025340608A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3178US12234300B2Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Granted Feb 25, 2025·0 cites·18 claims
- 3276US11884748B2Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·21 claims
- 3375US2022162261A1NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3472US2025327065A1Disulfide-rich peptide libraries and methods of use thereofPROTAGONIST THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3572US2020239523A1NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3671US2024132558A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3770US2024016895A1Hepcidin mimetics for treatment of sickle cell diseasePROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3870US2024066131A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3970US2024018189A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4069US12552836B2Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Granted Feb 17, 2026·0 cites·21 claims
- 4168US2023295259A1Conjugated Hepcidin MimeticsPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4267US2025360187A1Hepcidin mimetics for treatment of sickle cell diseasePROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4364US2023382998A1METHODS FOR TREATING INFLAMMATORY BOWEL DISEASES WITH a4B7 INTEGRIN ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4464US2025304624A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4564US2025361280A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4664US2018100004A1Hepcidin analogues and uses thereofPROTAGONIST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4762US2025170216A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4861US2018148477A1NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTSPROTAGONIST THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4961US2022041658A1Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseasesPROTAGONIST THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5060US2024209053A1Conjugated hepcidin mimeticsPROTAGONIST THERAPEUTICS INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when PROTAGONIST THERAPEUTICS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →